No Data
The current cycle of Traditional Chinese Medicine materials is entering a downturn phase, and pharmaceutical companies may face a cost "turning point."
In the second half of 2024, the prices of Traditional Chinese Medicine materials are expected to decline overall; the semi-annual and third quarter reports of this year show that the gross margin of some Chinese Patent Medicine listed companies has significantly decreased, indicating a notable impact of the fluctuation in Traditional Chinese Medicine material prices on costs. However, with the retreat in Traditional Chinese Medicine material prices, production costs for companies will also decrease.
Here's What To Make Of Shanghai Pharmaceuticals Holding's (SHSE:601607) Decelerating Rates Of Return
Sinolink: The end of year centralized purchasing expectations are gradually being cleared, and the pharmaceutical sector行情 is expected to gradually start.
The pharmaceutical Sector is currently in a process of a triple reversal in performance, policies, and funding, with full confidence in the recovery of revenue profit growth and market resurgence of listed companies in the Sector by 2025.
Shanghai Pharmaceuticals Gets Clinical Trial Approval for Varicose Vein Treatment
Shanghai Pharmaceuticals Gets US FDA Orphan Drug Designation for ALS Drug
SH PHARMA: SRD4610 has obtained orphan drug designation from the USA FDA.
On December 10, 2023, SH PHARMA (601607.SH) announced that its wholly-owned subsidiary, Shanghai Shangyao Ruir Pharmaceutical Co., Ltd., has independently developed SRD4610 for the treatment of amyotrophic lateral sclerosis (ALS) and received orphan drug designation from the USA Food and Drug Administration (referred to as "USA FDA"). SRD4610 is a compound Traditional Chinese Medicine Innovative Drug, and the project has completed a Phase II clinical trial for ALS in China.
Return Trends At Shanghai Pharmaceuticals Holding (SHSE:601607) Aren't Appealing
